Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Procedure: Placebo Surgery
- Registration Number
- NCT00876863
- Lead Sponsor
- Sangamo Therapeutics
- Brief Summary
The purpose of this study is to evaluate the potential benefits of CERE-110 in the treatment of Alzheimer's disease. CERE-110 is an experimental drug that is designed to help nerve cells in the brain function better. CERE-110 uses a virus to transfer a gene that makes Nerve Growth Factor (NGF), a protein that may make nerve cells in the brain healthier and protect them from dying. The virus used in CERE-110 does not cause disease in people. CERE-110 has been carefully studied in laboratory animals and is in the early stages of being tested in people.
Fifty patients with mild to moderate Alzheimer's disease will participate in this study. Half of the study subjects will have CERE-110 injected into the brain during a surgical procedure, while the other half will undergo a "placebo" surgery where no medication will be injected. All study participants will be followed for at least two years after surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 49
- Diagnosis of mild to moderate Alzheimer's disease
- Approved medications for Alzheimer's disease may be taken if the dose has been stable for 3 months
- A study partner who can attend all study visits
- Good general health
- Medically able to undergo neurosurgery
- Significant neurological disease other than Alzheimer's disease
- Significant depression or other psychiatric disorder
- Unstable medical conditions
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Surgery Placebo Surgery
- Primary Outcome Measures
Name Time Method Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) 24 Months
- Secondary Outcome Measures
Name Time Method Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) 24 Months Neuropsychological Test Battery 24 Months Mini-Mental State Examination (MMSE) 24 Months Neuropsychiatric Inventory (NPI) 24 Months
Trial Locations
- Locations (10)
Georgetown University
🇺🇸Washington, District of Columbia, United States
University of California, San Diego
🇺🇸San Diego, California, United States
University of Alabama
🇺🇸Birmingham, Alabama, United States
Medical University of South Carolina
🇺🇸North Charleston, South Carolina, United States
Mount Sinai School of Medicine
🇺🇸New York, New York, United States
Duke University
🇺🇸Durham, North Carolina, United States
University of Utah
🇺🇸Salt Lake City, Utah, United States
University of California, Los Angeles
🇺🇸Los Angeles, California, United States
Case Western Reserve University
🇺🇸Cleveland, Ohio, United States
Emory University
🇺🇸Atlanta, Georgia, United States